Income Insurance Ltd Invests $655,000 in Thermo Fisher Scientific Inc. $TMO

Income Insurance Ltd purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the fourth quarter, Holdings Channel.com reports. The fund purchased 1,131 shares of the medical research company’s stock, valued at approximately $655,000.

Other institutional investors also recently modified their holdings of the company. Assetmark Inc. grew its position in shares of Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after buying an additional 7,023 shares during the last quarter. Cornerstone Investment Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $41,393,000. Mackenzie Financial Corp boosted its position in shares of Thermo Fisher Scientific by 29.4% during the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock valued at $134,130,000 after purchasing an additional 62,790 shares in the last quarter. VELA Investment Management LLC boosted its position in shares of Thermo Fisher Scientific by 65.5% during the 3rd quarter. VELA Investment Management LLC now owns 9,305 shares of the medical research company’s stock valued at $4,513,000 after purchasing an additional 3,683 shares in the last quarter. Finally, NEOS Investment Management LLC boosted its position in shares of Thermo Fisher Scientific by 28.6% during the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock valued at $24,913,000 after purchasing an additional 11,415 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. TD Cowen cut their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Morgan Stanley restated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. UBS Group restated a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a research report on Friday, April 24th. Finally, Stifel Nicolaus cut their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research report on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $619.65.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 5,800 shares of company stock worth $2,963,544. Corporate insiders own 0.33% of the company’s stock.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Erste Group raised its FY2027 earnings estimate for Thermo Fisher, signaling slightly better long-term profit expectations for the company. Article
• Positive Sentiment: Thermo Fisher was included in CNBC’s “Final Trades,” which can reinforce investor interest and visibility in the stock. Article
• Neutral Sentiment: Thermo Fisher continues to be viewed as a key player in life sciences tools, and a new market note questioned whether the recent pullback makes the shares more attractive from a valuation standpoint. Article
• Neutral Sentiment: Proscia’s MedTech Breakthrough Award win mentioned Thermo Fisher among industry peers, but the item was focused on Proscia rather than a direct company-specific catalyst for TMO. Article
• Negative Sentiment: Wells Fargo cut its price target on Thermo Fisher from $675 to $615, which can weigh on sentiment even though the firm kept an overweight rating. Article

Thermo Fisher Scientific Stock Down 2.1%

Shares of NYSE:TMO opened at $464.64 on Friday. The business’s 50 day simple moving average is $493.53 and its two-hundred day simple moving average is $546.70. The firm has a market cap of $172.67 billion, a P/E ratio of 25.54, a PEG ratio of 2.06 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th were issued a $0.47 dividend. The ex-dividend date was Friday, March 13th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.